Loading...
Profile of tildrakizumab-asmn in the treatment of moderate-to-severe plaque psoriasis: evidence to date
Plaque psoriasis is an immune-mediated skin disease that affects roughly 3% of adults in the United States. Advances over the past 20 years in understanding the immune-mediated pathophysiology of psoriasis have led to the development of targeted biologic therapies for this condition. Currently, biol...
Saved in:
| Published in: | Psoriasis (Auckl) |
|---|---|
| Main Authors: | , , , |
| Format: | Artigo |
| Language: | Inglês |
| Published: |
Dove Medical Press
2018
|
| Subjects: | |
| Online Access: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6120577/ https://ncbi.nlm.nih.gov/pubmed/30214892 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/PTT.S146640 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|